HilleVax to Participate in JP Morgan Biotech – 2022 Conference Call Series
StreetInsider.com Top Tickers, 03/09/2022
News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.
BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines, today announced that it will participate in the JP Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax’s investigational virus particle (VLP) vaccine for the prevention of moderate to severe acute norovirus-related gastroenteritis, and related ongoing Phase 2b study NEST-IN1 will be the subjects of discussion.
|Fireside chat details:|
|Date:||Tuesday, September 6, 2022|
|Time:||1:00 p.m. – 2:00 p.m. Eastern Daylight Time (EDT)|
|Moderator:||Eric Joseph, Ph.D.|
|HilleVax Participant:||Robert Hershberg, MD, Ph.D., President and CEO|
Please contact your JP Morgan representative to access the session
About Hille Vax
HilleVax is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel vaccines. Its initial program, HIL-214, is a viral particle-based (VLP) vaccine candidate under development for the prevention of moderate to severe acute gastroenteritis caused by norovirus infection. Globally, norovirus is estimated to cause more than 700 million cases of AGE and 200,000 deaths per year, resulting in more than $4 billion in direct costs to the health care system and $60 billion in costs society per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.
Shane Maltbie[email protected]+1-617-213-5054
Source: HilleVax, Inc.
Serious news for serious traders! Try StreetInsider.com Premium for free!